← Eichor
Study identifier: NCT05556642 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative

Condition: Relapsed Hepatoblastoma · Refractory Hepatoblastoma  ·  Sponsor: Children's Hospital Medical Center, Cincinnati

PhaseN/A
Planned participants500
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

There are limited data regarding the biology and treatment of relapsed/refractory hepatoblastoma (rrHBL). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of rrHBL. This registry will collect clinical, demographic, and pathological data, specimens (as available) and imaging from patients with rrHBL, prospectively. Cases are identified through: 1. Existing clinical and/or cancer registry databases 2. Referrals from clinicians, surgeons, or pathologists 3. Families initiating contact with Registry staff directly

This description comes directly from the study's public registry record.

Talk to the study team

rrHBL Registry  ·  844-722-8774  ·  rrHBLRegistry@cchmc.org

Always discuss trial participation with your own doctor first.

Locations (1)

Cincinnati Children's Hospital Medical CenterCincinnati, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05556642